|Bid||100.60 x 1200|
|Ask||101.19 x 1000|
|Day's Range||96.40 - 101.11|
|52 Week Range||82.39 - 232.40|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal.
Madrigal Pharmaceuticals, Inc. (MDGL) announced today the promotion of Rebecca Taub, M.D., to the newly created positon of President of Research & Development. Dr. Taub has served as Chief Medical Officer and Executive Vice President of Research & Development, of Madrigal since 2016.
Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit.
CONSHOHOCKEN, Pa., June 04, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub,.
NEW YORK, May 15, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQCM: MDGL) concerning possible breaches of.
CONSHOHOCKEN, Pa., May 08, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to.
-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH.
Madrigal Pharmaceuticals, Inc. (MDGL) announced today that it has initiated its Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196 (resmetirom). This double-blind, placebo-controlled study will be conducted at more than 150 sites in the United States and the rest of the world.
CONSHOHOCKEN, Pa., Feb. 27, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights:.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
-- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class.
CONSHOHOCKEN, Pa., Nov. 06, 2018 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical.